Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Alzheimer's disease (AD) pathogenesis remains incompletely understood, hindering effective treatment development.
• Current therapies, primarily acetylcholinesterase (AChE) inhibitors, offer only symptomatic relief for AD patients.
• Emerging evidence suggests AChE possesses non-cholinergic roles in beta-amyloid (Abeta) processing and aggregation.

Purpose of the Study:

• To review the non-cholinergic functions of AChE in Alzheimer's disease.
• To explore the potential of targeting AChE for novel Alzheimer's disease therapeutics.
• To highlight compounds that inhibit AChE-induced amyloid aggregation.

Main Methods:

• Literature review of studies on AChE functions and Alzheimer's disease.
• Analysis of evidence linking AChE to beta-amyloid deposition.
• Identification and evaluation of novel AChE inhibitors with dual activity.

Main Results:

• AChE accelerates beta-amyloid deposition, playing a role in early senile plaque formation.
• Dual binding site AChE inhibitors show potential for AD treatment by targeting Abeta.
• Several compounds exhibit potent AChE inhibition and anti-amyloid aggregation activity.

Conclusions:

• AChE inhibition represents a promising therapeutic strategy for Alzheimer's disease, targeting both cholinergic and non-cholinergic pathways.
• New generations of AChE inhibitors targeting Abeta aggregation are emerging as potential disease-modifying treatments.
• Further research into AChE's non-classical functions could unlock more effective Alzheimer's disease therapies.